Results from the iAdhere trial (Study 33), conducted through the TB Trials Consortium, have been published in the Annals of Internal Medicine. This randomized trial aimed to compare treatment completion and safety of once-weekly isoniazid and rifapentine for latent TB infection by self-administration versus direct observation. The results of this study support using self-administered, once-weekly isoniazid and rifapentine to treat latent TB infection in the United States, and such treatment could be considered in similar settings when DOT is not feasible. Vanderbilt and Metro Nashville Public Health Department were participating sites in this trial.

Read the full article and accompanying editorials

Vanderbilt Institute for Infection, Immunology, and Inflammation (VI4) Seminar Series

Postdoc, Sassetti Lab at Univ of Massachussetts Medical School

512 Light Hall

Global Health Grand Rounds

8th Floor Videoconference Room